273 related articles for article (PubMed ID: 34051351)
61. Microbiomes in pancreatic cancer can be an accomplice or a weapon.
Guo X; Wang P; Li Y; Chang Y; Wang X
Crit Rev Oncol Hematol; 2024 Feb; 194():104262. PubMed ID: 38199428
[TBL] [Abstract][Full Text] [Related]
62. The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review.
Liu L; Shah K
JAMA Oncol; 2022 Jul; 8(7):1059-1067. PubMed ID: 35482355
[TBL] [Abstract][Full Text] [Related]
63. Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy.
Chrysostomou D; Roberts LA; Marchesi JR; Kinross JM
Gastroenterology; 2023 Feb; 164(2):198-213. PubMed ID: 36309208
[TBL] [Abstract][Full Text] [Related]
64. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Riquelme E; Zhang Y; Zhang L; Montiel M; Zoltan M; Dong W; Quesada P; Sahin I; Chandra V; San Lucas A; Scheet P; Xu H; Hanash SM; Feng L; Burks JK; Do KA; Peterson CB; Nejman D; Tzeng CD; Kim MP; Sears CL; Ajami N; Petrosino J; Wood LD; Maitra A; Straussman R; Katz M; White JR; Jenq R; Wargo J; McAllister F
Cell; 2019 Aug; 178(4):795-806.e12. PubMed ID: 31398337
[TBL] [Abstract][Full Text] [Related]
65. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
66. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy.
Zhang X; Liu Q; Liao Q; Zhao Y
J Cancer; 2020; 11(10):2749-2758. PubMed ID: 32226493
[TBL] [Abstract][Full Text] [Related]
67. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
68. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
69. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications.
Zhao LY; Mei JX; Yu G; Lei L; Zhang WH; Liu K; Chen XL; Kołat D; Yang K; Hu JK
Signal Transduct Target Ther; 2023 May; 8(1):201. PubMed ID: 37179402
[TBL] [Abstract][Full Text] [Related]
70. Modeling pancreatic cancer in mice for experimental therapeutics.
Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
[TBL] [Abstract][Full Text] [Related]
71. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
72. Bile Acids and Microbiota Interplay in Pancreatic Cancer.
Malhotra P; Palanisamy R; Caparros-Martin JA; Falasca M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509236
[TBL] [Abstract][Full Text] [Related]
73. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
74. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
75. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
76. Gut microbiota modulation of chemotherapy efficacy and toxicity.
Alexander JL; Wilson ID; Teare J; Marchesi JR; Nicholson JK; Kinross JM
Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):356-365. PubMed ID: 28270698
[TBL] [Abstract][Full Text] [Related]
77. The gut microbiome and efficacy of cancer immunotherapy.
Roviello G; Iannone LF; Bersanelli M; Mini E; Catalano M
Pharmacol Ther; 2022 Mar; 231():107973. PubMed ID: 34453999
[TBL] [Abstract][Full Text] [Related]
78. The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
Brandi G; Turroni S; McAllister F; Frega G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576078
[TBL] [Abstract][Full Text] [Related]
79. Interaction between gut microbiota and tumour chemotherapy.
Liu L; Bai Y; Xiang L; Qi W; Gao L; Li X; Li H; Wang B; Chen H
Clin Transl Oncol; 2022 Dec; 24(12):2330-2341. PubMed ID: 36103048
[TBL] [Abstract][Full Text] [Related]
80. Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling.
Riquelme E; Maitra A; McAllister F
Cancer Discov; 2018 Apr; 8(4):386-388. PubMed ID: 29610286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
